SCHEMBL5135900

SCHEMBL5135900

CCCCn1c(CN(Cc2ccccc2)Cc2ccc(N(C)C)cc2)cnc1-c1ccc(OC)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR7 Q9NYK1 1/20 0.42
PDE6D O43924 1/20 0.39
RAB9A P51151 2/20 0.39
NPC1 O15118 1/20 0.39
SMPD1 P17405 1/20 0.38
LTB4R2 Q9NPC1 1/20 0.38
ALDH1A1 P00352 6/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
GAA P10253 2/20 0.38
TP53 P04637 2/20 0.38
MAPT P10636 2/20 0.38
MAPK1 P28482 2/20 0.38
MCL1 Q07820 1/20 0.38
KDM4E B2RXH2 2/20 0.37
HPGD P15428 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
HSD17B10 Q99714 2/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
NPSR1 Q6W5P4 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5138093 0.92 TSHR (0.43) RAB9ANPC1SMPD1ALDH1A1L3MBTL1
SCHEMBL5135816 0.91 TSHR (0.44) TLR7RAB9ANPC1ALDH1A1L3MBTL1
SCHEMBL5072318 0.87 TSHR (0.40) RAB9ASMPD1LTB4R2ALDH1A1L3MBTL1
SCHEMBL5134787 0.86 BCHE (0.42) SMPD1L3MBTL1TSHRBCHE
SCHEMBL14415533 0.86 ALDH1A1 (0.39) TLR7ALDH1A1L3MBTL1GAATP53
SCHEMBL14415595 0.84 HPGD (0.44) RAB9AALDH1A1L3MBTL1MAPTHPGD
SCHEMBL5135645 0.84 TAS2R14 (0.44) RAB9ANPC1SMN1; SMN2
SCHEMBL5072278 0.84 TSHR (0.51) ALDH1A1MAPK1KDM4EHPGDSMN1; SMN2
SCHEMBL5135378 0.83 CALM1 (0.45) TLR7ALDH1A1GAAMAPTMAPK1
SCHEMBL5135023 0.83 AGTR1 (0.45) MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed